Related Experiment Video
Updated: Jan 21, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
Published on: June 5, 2015
Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In
Narasimha Rao Uda1,2, Frank Stenner3,4, Volker Seibert5,6
1Cancer Immunology Laboratory, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland christoph.renner@unibas.ch narasimha.uda@unige.ch.
Background/Aim:
Carbonic anhydrase 12 (CA12) is a membrane-associated enzyme that is highly expressed on many human cancers. It is a poor prognostic marker and hence an attractive target for cancer therapy. This study aimed to develop a humanized CA12-antibody with anti-cancer activity.
Materials And Methods:
Antibody libraries were constructed and screened by the Retrocyte display®. Antibody binding and blocking properties were determined by ELISA, flow cytometry and enzymatic activity assays. Spheroid viability was determined by Cell-Titer-Fluor assay.
Results:
We developed a novel humanized CA12-specific antibody, 4AG4, which recognized CA12 as an antigen and blocked CA12 enzymatic activity. Our humanized CA12-antibody significantly inhibited spheroid growth of lung adenocarcinoma A549-cells in vitro by blocking CA12 enzymatic activity. Similar anti-tumor effects were recapitulated with CA12-gene knockout of A549-cells.
Conclusion:
Our newly identified humanized CA12-antibody with anti-cancer activity, represents a new tool for the treatment of CA12-positive tumors.
Insights
Researchers developed a humanized carbonic anhydrase 12 (CA12) antibody, 4AG4, that inhibits cancer cell growth. This novel antibody targets CA12-positive tumors, offering a new therapeutic avenue.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Carbonic anhydrase 12 (CA12) is a membrane enzyme overexpressed in many human cancers.
- High CA12 expression correlates with poor prognosis, making it a promising therapeutic target.
- Developing targeted therapies against CA12 is crucial for effective cancer treatment.
Purpose of the Study:
- To develop a humanized antibody targeting carbonic anhydrase 12 (CA12).
- To evaluate the anti-cancer activity of the developed CA12-specific antibody.
- To assess the antibody's potential as a therapeutic agent for CA12-positive tumors.
Main Methods:
- Construction and screening of antibody libraries using Retrocyte display®.
- Characterization of antibody binding and blocking activity via ELISA, flow cytometry, and enzymatic assays.
- Assessment of spheroid viability using Cell-Titer-Fluor assay.
Main Results:
- A novel humanized CA12-specific antibody, designated 4AG4, was successfully developed.
- The 4AG4 antibody recognized CA12 and effectively blocked its enzymatic activity.
- Significant inhibition of lung adenocarcinoma (A549) spheroid growth was observed in vitro, mediated by CA12 enzymatic blockade.
- Comparable anti-tumor effects were achieved using CA12-gene knockout A549 cells.
Conclusions:
- The newly developed humanized CA12-antibody (4AG4) demonstrates significant anti-cancer activity.
- This antibody represents a novel therapeutic tool for targeting CA12-positive tumors.
- Targeting CA12 enzymatic activity is a viable strategy for developing new cancer treatments.
Related Concept Videos
The Carbon Cycle
Carbon Skeletons
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Phase-lead and Phase-lag Controllers
Block Diagram Reduction
The first step in this process is the identification and relocation of a branch point. A branch point, where a...
Carbonation Shrinkage
The concrete's permeability is slightly reduced as calcium carbonate produced during the reaction fills its pores. Furthermore, its strength is slightly enhanced as the water released during the reaction...

